Phase I and Pharmacokinetic Study of Oral Irinotecan Given Once Daily for 5 Days Every 3 Weeks in Combination With Capecitabine in Patients With Solid Tumors
Authors:
- 1 February 2005
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (4) , 889-898
Abstract
Purpose: To assess the maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, and preliminary antitumor activity of oral irinotecan given in combination with capecitabine to patients with advanced, refractory solid tumors. Patients and Methods: Patients were treated from day 1 with irinotecan capsules given once daily for 5 consecutive days (50 to 60 mg/m2/d) concomitantly with capecitabine given twice daily for 14 consecutive days (800 to 1,000 mg/m2); cycles were repeated every 21 days. Results: Twenty-eight patients were enrolled and received 155 cycles of therapy (median, five cycles; range, one to 18 cycles). With irinotecan 60 mg/m2/d and capecitabine 2 × 800 mg/m2/d, grade 3 delayed diarrhea in combination with grade 2 nausea (despite maximal antiemetic support) and grade 3 anorexia and colitis, were the first-cycle dose-limiting toxicities in two of six patients, respectively. At the recommended doses (irinotecan 50 mg/m2/d; capecitabine 2 × 1,000 mg/m2/d), side effects were mostly mild to moderate and uniformly reversible. Pharmacokinetic analysis showed that there was no interaction between oral irinotecan and capecitabine, and that body-surface area was not significantly contributing to the observed pharmacokinetic variability. Confirmed partial responses were observed in two patients with gallbladder carcinoma and in one patient with melanoma. Disease stabilization was noted in 16 patients. Conclusion: The recommended phase II doses for oral irinotecan and capecitabine are 50 mg/m2/d for 5 consecutive days, and 2 × 1,000 mg/m2/d for 14 consecutive days repeated every 3 weeks, respectively.Keywords
This publication has 21 references indexed in Scilit:
- Clinical Pharmacokinetic/Pharmacodynamic and Physiologically based Pharmacokinetic Modeling in New Drug Development: The Capecitabine ExperienceInvestigational New Drugs, 2003
- Lessons Learned from the Irinotecan Metabolic PathwayCurrent Medicinal Chemistry, 2003
- Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001JNCI: Journal of the National Cancer Institute, 2002
- Phase I Clinical Trial of Irinotecan With Oral Capecitabine in Patients With Gastrointestinal and Other Solid MalignanciesAmerican Journal of Clinical Oncology, 2002
- Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrheaClinical Pharmacology & Therapeutics, 2002
- CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (MCRC): preliminary results of a phase I/II studyEuropean Journal of Cancer, 2001
- Clinical Pharmacokinetics of CapecitabineClinical Pharmacokinetics, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicityCancer Chemotherapy and Pharmacology, 1998
- Clinical Pharmacokinetics of IrinotecanClinical Pharmacokinetics, 1997